Salim Syed
Stock Analyst at Mizuho
(1.93)
# 3,007
Out of 4,868 analysts
81
Total ratings
36.92%
Success rate
-8.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $1.77 | +690.96% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $32.43 | +159.02% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $127.04 | +33.03% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $289.33 | -3.22% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $108.50 | +7.83% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $6.57 | +234.86% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $32.86 | +396.04% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $7.86 | +129.01% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $21.29 | +59.70% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $44.25 | +123.73% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $41.73 | +27.01% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $0.80 | +649.91% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $0.75 | +2,710.49% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $17.26 | +108.57% | 1 | Nov 16, 2022 |
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $1.77
Upside: +690.96%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $32.43
Upside: +159.02%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $127.04
Upside: +33.03%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $289.33
Upside: -3.22%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $108.50
Upside: +7.83%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $6.57
Upside: +234.86%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $32.86
Upside: +396.04%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $7.86
Upside: +129.01%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $21.29
Upside: +59.70%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $44.25
Upside: +123.73%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $41.73
Upside: +27.01%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $0.80
Upside: +649.91%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $0.75
Upside: +2,710.49%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $17.26
Upside: +108.57%